Novartis sponsored a symposium at the COPHy congress in 2012 exploring the current treatment issues surrounding wet AMD. This supplement reveals the highlights of the meeting.
Internal limiting membrane staining dye ILM-Blue from DORC (Zeiss) receives NMPA approval in China
The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Nanoscope Therapeutics publishes clinical results of MCO-010 findings for patients with retinitis pigmentosa
The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports
The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration
Study examines real-world treat-and-extend outcomes and background factors of macular atrophy
The study demonstrated that the number of injections needed gradually decreased during the follow-up period